PALISADE BIO, INC. Line of Credit Facility, Maximum Amount Outstanding During Period
PALISADE BIO, INC. (PALI) reported Line of Credit Facility, Maximum Amount Outstanding During Period of $10.00 million for the 1-month period ending 2014-10-31, per its 10-K filed 2015-03-16.
Discontinued › Notes › Debt › Line of Credit Facility
us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod · last filed 2015-03-16
- 2014-10-31: Line of Credit Facility, Maximum Amount Outstanding During Period 1 month $10.00M.
| Period end | Line of Credit Facility, Maximum Amount Outstanding During Period 1 month |
|---|---|
| 2014-10-31 | $10.00M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |